Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)
CPRX recently reported that a poster presentation demonstrating that CPP-115, Catalyst’s next-generation GABA aminotransferase inhibitor, suppresses infantile spasms (IS) in the rat multiple-hit model will be made on December 3, 2011 at the American Epilepsy Society’s 65th Annual Meeting (AES) to be held December 2-6, 2011 at the Baltimore Convention Center in Baltimore, Maryland.
IS is an infantile epileptic encephalopathy associated with cognitive and behavioral deficits and increased mortality. Vigabatrin (CPP-109), a GABA transaminase inhibitor, is one of the few treatments available for IS. The study tested the efficacy in suppressing spasms and tolerability profile of Catalyst’s new vigabatrin analog, CPP-115, in the multiple-hit rat model of ACTH-refractory symptomatic IS (DLP model). This model recreates the spasms, ictal EEG correlates, interictal EEG abnormalities, and neurodevelopmental decline observed in symptomatic infantile spasms observed in babies. In the later stages of development, the rats also develop learning, memory, and autistic like deficits similar to those observed in humans. It is therefore, currently one of the best models available for the evaluation of pharmacotherapies for the treatment of ACTH resistant infantile spasms. In previous studies, vigabatrin only transiently suppressed spasms in the DLP model (postnatal day 5 (PN5) only), but was associated with increased sedation and consequently mortality due to poor feeding. The poster describes the following study conclusions:
1. CPP-115 suppresses spasms in the multiple-hit model of IS, with onset of effect as early as the day after the first dose.
2. The therapeutic doses of CPP-115 were well tolerated in developing rat pups.
3. CPP-115 showed efficacy at lower doses which were better tolerated than the previously tested therapeutic vigabatrin (CPP-109) doses.
CPRX is developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin.CPRX is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and for other selected central nervous disease indications. CPP-115 has been granted orphan-drug designation for the treatment of infantile spasms by the FDA. CPRX believes that it controls all current intellectual property for drugs that have a mechanism of action related to the inhibition of GABA aminotransferase.
The poster can be viewed on December 3, 2011, between 11:00 AM and 5:30 PM ET (poster number 1.280), with the opportunity to discuss the results of this study with some of the authors from 11:00 AM to 12:45 PM ET.
CPRX is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.
For more information about CPRX please visit http://www.catalystpharma.com/
Nexen Inc. (NYSE: NXY) announced that they have concluded a joint venture with CNOOC Limited in the Gulf of Mexico. The joint venture will give CNOOC Limited a working interest in up to six deepwater exploration wells in the Gulf. Among the prospects included in the deal are the Kakuna well, which is currently drilling, and the Angel Fire well, which is expected to spud in 2012. CNOOC Limited will participate in Kakuna, Angel Fire, and Cypress with a 20% working interest. CNOOC Limited may also participate in three additional exploration wells with a 10% to 25% working interest. The venture does not include any interest in our Appomattox discovery or related Norphlet formation prospects.
Nexen Inc. operates as an independent energy company worldwide. Its Oil and Gas segment explores for, develops, and produces crude oil, natural gas, and related products.
Cleantech Transit Inc. (CLNO)
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
Biomass has many advantages. Some of them are given below;
Biomass used as a fuel reduces need for fossil fuels for the production of heat, steam, and electricity for residential, industrial and agricultural use.
Biomass is always available and can be produced as a renewable resource.
Biomass fuel from agriculture wastes may be a secondary product that adds value to agricultural crop.
Growing Biomass crops produce oxygen and use up carbon dioxide.
The use of waste materials reduce landfill disposal and makes more space for everything else.
Carbon Dioxide which is released when Biomass fuel is burned is taken in by plants.
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net).
Lincoln Financial Group (NYSE:LNC) will participate in the Goldman Sachs Financial Services Conference on Wednesday, December 7, 2011 at approximately 10:00 a.m. ET . Dennis Glass, president and chief executive officer, will discuss the company’s business performance and strategies. Interested persons are invited to listen through the Internet and view the presentation slides, either live or through on-demand replay. Please go to www.LincolnFinancial.com/webcast at least fifteen minutes prior to the event to register and download any necessary streaming media software and presentation materials.
Lincoln Financial Group is the marketing name for Lincoln National Corporation and its affiliates. With headquarters in the Philadelphia region, the companies of Lincoln Financial Group had assets under management of $153 billion as of September 30, 2011.
Alaska Air Group Inc. (NYSE:ALK) reported November operational results for its subsidiaries, Alaska Airlines and Horizon Air, and on a combined basis. Alaska reported a 7.8 percent increase in traffic on a 4.8 percent increase in capacity compared to November 2010. This resulted in a 2.5-point increase in load factor to a November record 86.4 percent. Alaska also reported 84.8 percent of its flights arrived on time in November, compared to the 82.5 percent reported in November 2010. Horizon reported a 15.3 percent decline in traffic on an 18.8 percent decline in capacity compared to November 2010. This resulted in a 3.3-point increase in load factor to a November record of 79.3 percent. Horizon also reported a November record 88.9 percent of its flights arrived on time, compared to the 70.9 percent reported in November 2010. The significant decline in capacity and traffic for Horizon from 2010 is due primarily to the completion of Horizon’s transition out of the CRJ-700 fleet and a corresponding reduction in the size of the carrier’s operating fleet from 54 aircraft at Nov. 31, 2010 , to 48 aircraft at Nov. 31, 2011 . This transition was completed in June of 2011.
Alaska Air Group, Inc., through its subsidiaries, Alaska Airlines, Inc. and Horizon Air Industries, Inc., operates as an airline company serving destinations in the western United States, Canada, and Mexico.
No comments:
Post a Comment